Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist.
Numerous reports have implicated theY5 receptor as the 'feeding' receptor mediating the orexigenic action of neuropeptide Y (NPY). This notion is supported by the correlation between the in vitro functional and binding activities of different peptide agonists and their potent stimulation of food intake in rodents. We have discovered a series of small molecule heterocycles with high affinity, selectivity, and functional antagonism for Y5 receptors. Intraperitoneal (i.p.) administration of GW438014A into rodents, resulted in a potent reduction of NPY-induced and normal overnight food intake. Brain levels of GW438014A were detected well in excess of its binding IC(50) for up to 3 h post-dosing. Daily (i.p., BID, 10 mg/kg) administration of this compound to Zucker Fatty rats for a period of 4 days resulted in a marked decrease in the rate of weight gain and a reduction in fat mass. No effect on food intake was observed following oral administration of GW438014A (25-100 mg/kg), consistent with the poor oral bioavailability (<3%) and low brain levels observed.
Daniels
A J
AJ
GlaxoSmithKline, Department of Metabolic Diseases, Research Triangle Park, NC 27709, USA. ajd32553@gsk.com
Grizzle
M K
MK
Wiard
R P
RP
Matthews
J E
JE
Heyer
D
D
D000273:Adipose Tissue / Q000187:drug effects; D000284:Administration, Oral; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D005247:Feeding Behavior / Q000187:drug effects*; D008297:Male; D015394:Molecular Structure; D009765:Obesity / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011924:Rats, Zucker; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors*; D013851:Thinness / Q000378:metabolism*; D015430:Weight Gain / Q000187:drug effects*
D001562:Benzimidazoles; C470485:GW438014A; D017476:Receptors, Neuropeptide Y; C100568:neuropeptide Y5 receptor